Coronavirus Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers
Conditions: Coronavirus Interventions: Biological: OVX033; Biological: Saline solution Sponsors: Osivax; Centre for the Evaluation of Vaccination H ôpital Cochin Assistance Publique - Hôpitaux de Paris (APHP) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 13, 2023 Category: Research Source Type: clinical trials

Evaluation of Concordance Between Exhaled Air Test (eBAM-CoV) and RT-PCR to Detect SARS-CoV-2
Conditions: SARS-CoV-2 Infection; COVID-19; Coronavirus Interventions: Device: eBAM Cov Testing Sponsors: Centre Hospitalier Universitaire de N īmes; University of Nimes; brains ' laboratory sas, FRANCE Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 25, 2023 Category: Research Source Type: clinical trials

Frequency of screening and SBT Technique Trial —North American Weaning Collaboration (FAST-NAWC): an update to the protocol and statistical analysis plan
AbstractBackgroundThis update summarizes key changes made to the protocol for the Frequency of Screening and Spontaneous Breathing Trial (SBT) Technique Trial —North American Weaning Collaborative (FAST-NAWC) trial since the publication of the original protocol. This multicenter, factorial design randomized controlled trial with concealed allocation, will compare the effect of both screening frequency (once vs. at least twice daily) to identify candidat es to undergo a SBT and SBT technique [pressure support + positive end-expiratory pressure vs. T-piece] on the time to successful extubation (primary outcome) in 760 ...
Source: Trials - October 2, 2023 Category: Research Source Type: clinical trials

Omicron BA.4/5-Delta COVID-19 Vaccine Phase I Clinical Trial
Condition: COVID-19 Interventions: Biological: Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells); Biological: Placebo Sponsors: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.; Hunan Provincial Center for Disease Control and Prevention Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials

SA55 Novel Coronavirus Broad-spectrum Neutralizing Antibody Nasal Spray in Health People
Condition: COVID-19 Intervention: Drug: SA55 nasal spray Sponsor: Sinovac Life Sciences Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials